Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04531527 · ClinicalTrials.gov registry record · Phase 3
Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
A Phase 3 study of Dermatitis, Phototoxic, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04531527 is a Phase 3 study of Dermatitis, Phototoxic that has completed, run by Bayer. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04531527, a Phase 3 study of Dermatitis, Phototoxic, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study researchers want to gather information about the potential of Antifungal Cream V61-044 containing Trolamine to produce a phototoxic reaction on the skin. A phototoxic reaction is an irritant reaction of the skin to ultra violet light. In order to find this out the study drug will be applied to the skin of healthy human subjects. By using a solar simulator to generate a UV spectrum similar to that of sunlight the potential of the study drug to produce a superficial reddening of the skin will be measured.
Conditions Studied
Interventions
- DRUG Butenafine HCl 1% (BAY1896425)
Study Locations (1)
New Jersey
- - Fairfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-06-24 |
| Est. Completion | 2013-06-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04531527
The ClinicalTrials.gov registry entry for NCT04531527 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatitis, Phototoxic appearing as the primary indexed condition, and to 1 intervention - of which Butenafine HCl 1% (BAY1896425) is the first listed.
NCT04531527 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT04531527 about?
NCT04531527 is a clinical study titled "Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects". In this study researchers want to gather information about the potential of Antifungal Cream V61-044 containing Trolamine to produce a phototoxic reaction on the skin. A phototoxic reaction is an irritant reaction of the skin to ultra violet light. In order to find this out the study drug will be ap...
What is the current status of trial NCT04531527?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2013-06-24. Estimated completion is 2013-06-28.
What conditions does trial NCT04531527 study?
This clinical trial studies the following conditions: Dermatitis, Phototoxic.
What interventions are being tested in trial NCT04531527?
The interventions under investigation include: Butenafine HCl 1% (BAY1896425) (DRUG).
Who is sponsoring clinical trial NCT04531527?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04531527 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.